Journal of Biological Chemistry · 2006 · 112 citations · 41 references
Life SciencesCell BiologyHematologyCell SignalingMolecular Cell BiologyStem Cell BiologyCell Cycle SignalingCell Cycle TransitionsCell-cycle DysregulationCell-cycle RegulationHematopoietic Stem Cell BiologyMyeloproliferative NeoplasmsCell Cycle InhibitionCell Cycle InhibitorsG1 Cell-cycle ArrestG1-s Phase TransitionJak InhibitorsJak-stat Signaling PathwayJak2 MutationsJak2 V617f Mutation
Hematopoietic stem cells in myeloproliferative diseases mostly retain the potential to differentiate but are characterized by hyper-responsiveness to growth factors, as well as partial factor-independent growth. The V617F activating point mutation in Jak2 has recently been associated with myeloproliferative disorders. Using various cell line models, mechanisms that contribute to Jak2V617-mediated signaling were investigated. Treatment of the Jak2V617F mutant-expressing erythroid leukemia cell line HEL with a small molecule Jak2 inhibitor was associated with a dose-dependent G1 cell cycle arrest. This inhibition correlated with decreased expression of cyclin D2 and increased expression of the cell cycle inhibitor p27Kip. Inhibition of Jak2V617F with a Jak2-targeted small interfering RNA approach resulted in a similar phenotype. Mechanisms leading to altered p27Kip and cyclin D2 likely involve inhibition of STAT5, a major target of Jak2 in hematopoietic cells, because a constitutively active form of STAT5 reduced p27Kip and increased cyclin D2 expression. Jak2V617F and constitutively active STAT5 also induced high levels of reactive oxygen species, which are sufficient to promote G1/S phase transition. In contrast, treatment of HEL cells with the antioxidant N-acetylcysteine decreased cell growth or expression of cyclin D2 and increased expression of p27Kip. Similar results were obtained in BaF3 cells transfected with Jak2V617F, but these cells required coexpression of the erythropoietin receptor for optimal signaling. These results suggest that regulation of cyclin D2 and p27Kip in combination with redox-dependent processes promotes G1/S phase transition downstream of Jak2V617F/STAT5 and therefore hint at potential novel targets for drug development that may aid traditional therapy. Hematopoietic stem cells in myeloproliferative diseases mostly retain the potential to differentiate but are characterized by hyper-responsiveness to growth factors, as well as partial factor-independent growth. The V617F activating point mutation in Jak2 has recently been associated with myeloproliferative disorders. Using various cell line models, mechanisms that contribute to Jak2V617-mediated signaling were investigated. Treatment of the Jak2V617F mutant-expressing erythroid leukemia cell line HEL with a small molecule Jak2 inhibitor was associated with a dose-dependent G1 cell cycle arrest. This inhibition correlated with decreased expression of cyclin D2 and increased expression of the cell cycle inhibitor p27Kip. Inhibition of Jak2V617F with a Jak2-targeted small interfering RNA approach resulted in a similar phenotype. Mechanisms leading to altered p27Kip and cyclin D2 likely involve inhibition of STAT5, a major target of Jak2 in hematopoietic cells, because a constitutively active form of STAT5 reduced p27Kip and increased cyclin D2 expression. Jak2V617F and constitutively active STAT5 also induced high levels of reactive oxygen species, which are sufficient to promote G1/S phase transition. In contrast, treatment of HEL cells with the antioxidant N-acetylcysteine decreased cell growth or expression of cyclin D2 and increased expression of p27Kip. Similar results were obtained in BaF3 cells transfected with Jak2V617F, but these cells required coexpression of the erythropoietin receptor for optimal signaling. These results suggest that regulation of cyclin D2 and p27Kip in combination with redox-dependent processes promotes G1/S phase transition downstream of Jak2V617F/STAT5 and therefore hint at potential novel targets for drug development that may aid traditional therapy. The family of non-receptor Janus tyrosine kinases (Jaks) is comprised of four members, including Jak1, Jak2, Jak3, and Tyk2 (see for review Ref. 1Yamaoka K. Saharinen P. Pesu M. Holt V.E. III Silvennoinen O'Shea O.J.J. Genome Biol. 2004; 5: 253Crossref PubMed Scopus (459) Google Scholar). The Jaks contain seven regions with significant sequence homology between the kinases, termed Jak homology (JH) 2The abbreviations used are: JH, Jak homology; EpoR, erythropoietin receptor; GFP, green fluorescent protein; EGFP, enhanced GFP; PDTC, pyrrolidine dithiocarbamate; siRNA, small interfering RNA; FACS, fluorescence-activated cell sorter; ROS, reactive oxygen species; DCF-DA, 2′,7′-dichlorofluorescin diacetate; NAC, N-acetylcysteine. domains. The JH1 domain is located within the carboxyl terminus of the protein and contains the tyrosine kinase domain. The adjacent JH2 domain shows close homology to the JH1 domain. The JH2 domain lacks critical residues required for tyrosine kinase activity. This JH2 pseudokinase domain negatively regulates the kinase activity associated with the JH1 domain (2Saharinen P. Vihinen M. Silvennoinen O. Mol. Biol. Cell. 2003; 14: 1448-1459Crossref PubMed Scopus (177) Google Scholar, 3Luo H. Rose P. Barber D. Hanratty W.P. Lee S. Roberts T.M. D'Andrea A.D. Dearolf C.R. Mol. Cell. Biol. 1997; 17: 1562-1571Crossref PubMed Scopus (212) Google Scholar). Jaks are thought to primarily tyrosine phosphorylate and thus activate STAT (signal transducer and activator of transcription) transcription factors, although it seems clear that there are other activities. The Jak/STAT pathway has been implicated in a variety of solid tumors, as well as hematologic disorders. In particular, oncogenic fusion proteins of Jak2 with ETV6, PCM1, or BCR have been described in different leukemias and myeloproliferative disorders (4Peeters P. Raynaud S.D. Cools J. Wlodarska I. Grosgeorge J. Philip P. Monpoux F. Van Rompaey L. Baens M. Van den Berghe H. Marynen P. Blood. 1997; 90: 2535-2540Crossref PubMed Google Scholar, 5Lacronique V. Boureux A. Valle V.D. Poirel H. Quang C.T. Mauchauffe M. Berthou C. Lessard M. Berger R. Ghysdael J. Bernard O.A. Science. 1997; 278: 1309-1312Crossref PubMed Scopus (682) Google Scholar, 6Reiter A. Walz C. Watmore A. Schoch C. Blau I. Schlegelberger B. Berger U. Telford N. Aruliah S. Yin J.A. Vanstraelen D. Barker H.F. Taylor P.C. O'Driscoll A. Benedetti F. Rudolph C. Kolb H.J. Hochhaus A. Hehlmann R. Chase A. Cross N.C. Cancer Res. 2005; 65: 2662-2667Crossref PubMed Scopus (243) Google Scholar, 7Griesinger F. Hennig H. Hillmer F. Podleschny M. Steffens R. Pies A. Wormann B. Haase D. Bohlander S.K. Genes Chromosomes Cancer. 2005; 44: 329-333Crossref PubMed Scopus (125) Google Scholar). It has been suggested that elevated Jak2 tyrosine kinase activity contributes to transformation, likely in part through the STAT5 transcription factor. Genetic modeling suggests that STAT5 genes support immature hematopoiesis, as mice with a targeted disruption of the STAT5A and STAT5B genes have reduced myeloid progenitor counts (8Teglund S. McKay C. Schuetz E. van Deursen J.M. Stravopodis D. Wang D. Brown M. Bodner S. Grosveld G. Ihle J.N. Cell. 1998; 93: 841-850Abstract Full Text Full Text PDF PubMed Scopus (1080) Google Scholar). Furthermore, STAT5 may also be required for normal fetal erythropoiesis (9Socolovsky M. Fallon A.E. Wang S. Brugnara C. Lodish H.F. Cell. 1999; 98: 181-191Abstract Full Text Full Text PDF PubMed Scopus (618) Google Scholar). A close link of Jak2 kinase activity to STAT5 activation is also consistent with the fact that Jak2 knock-out mice have severely disrupted hematopoiesis that resembles the phenotype in mice with erythropoietin or erythropoietin receptor gene disruption (10Neubauer H. Cumano A. Muller M. Wu H. Huffstadt U. Pfeffer K. Cell. 1998; 93: 397-409Abstract Full Text Full Text PDF PubMed Scopus (682) Google Scholar, 11Parganas E. Wang D. Stravopodis D. Topham D.J. Marine J.C. Teglund S. Vanin E.F. Bodner S. Colamonici O.R. van Deursen J.M. Grosveld G. Ihle J.N. Cell. 1998; 93: 385-395Abstract Full Text Full Text PDF PubMed Scopus (912) Google Scholar, 12Wu H. Liu X. Jaenisch R. Lodish H.F. Cell. 1995; 83: 59-67Abstract Full Text PDF PubMed Scopus (861) Google Scholar, 13Lin C.S. Lim S.K. D'Agati V. Costantini F. Genes Dev. 1996; 10: 154-164Crossref PubMed Scopus (353) Google Scholar, 14Kieran M.W. Perkins A.C. Orkin S.H. Zon L.I. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 9126-9131Crossref PubMed Scopus (147) Google Scholar). An additional activating mutation of Jak2 has been recently reported in patients with polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis as well as in several myeloproliferative disorders and infrequently in myelodysplastic syndromes (15Levine R.L. Wadleigh M. Cools J. Ebert B.L. Wernig G. Huntly B.J. Boggon T.J. Wlodarska I. Clark J.J. Moore S. Adelsperger J. Koo S. Lee J.C. Gabriel S. Mercher T. D'Andrea A. Frohling S. Dohner K. Marynen P. Vandenberghe P. Mesa R.A. Tefferi A. Griffin J.D. Eck M.J. Sellers W.R. Meyerson M. Golub T.R. Lee S.J. Gilliland D.G. Cancer Cell. 2005; 7: 387-397Abstract Full Text Full Text PDF PubMed Scopus (2484) Google Scholar, 16James C. Ugo V. Le Couedic J.P. Staerk J. Delhommeau F. Lacout C. Garcon L. Raslova H. Berger R. Bennaceur-Griscelli A. Villeval J.L. Constantinescu S.N. Casadevall N. Vainchenker 2005; PubMed Scopus Google Scholar, C. N. S. N. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar, R. F. R. A. M. N. J. 2005; PubMed Scopus Google Scholar, R. S. X. J. Biol. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar, S. K. K. C. L. J. R. Chase H. C. D. E. B. M. T. E. Hehlmann R. Hochhaus A. D. A. Cross N.C. Blood. 2005; PubMed Scopus Google Scholar, R.L. Gilliland D.G. Tefferi A. Blood. 2005; PubMed Scopus Google Scholar). The point mutation leading to a V617F in the JH2 domain of Jak2 has been associated with the likely by leading to kinase activity. The for Jak2 activation are and may the to signaling mechanisms by Jak2V617F and targets that aid in the development and of targeted for the treatment of disorders. cell line and the cell line HEL were in fetal HEL cells were with The BaF3 cell line with active STAT5 was as described F. Griffin J.D. Blood. PubMed Google Scholar). STAT5 expression was induced by treatment with in the of cells the erythropoietin and cells Jak2V617F enhanced green protein were by A. D'Andrea Cancer and G. and BaF3 and cell were in BaF3 cell were by with or by G. In cells were with Jak inhibitor N-acetylcysteine pyrrolidine or transfected with Jak2 growth and was by or by a In between and were of and were used to HEL cells in of to the the In the was transfected to were to and at in were by of by the for were cells in and with inhibitor STAT5 cyclin D2 p27Kip Jak2 Jak2 or STAT5 and by T. Cancer or were used for or was by to the in cells that were with Jak inhibitor cells transfected with siRNA, or were with in and for of for at were with at for at cycle were by a The for was used to cell cycle of was used to the levels of in to various were and the levels of were the were with for at and in a A Jak G1 and in HEL V617F activating point mutation of the Jak2 tyrosine kinase has been to be sufficient for the of a myeloproliferative phenotype cells in C. Ugo V. Le Couedic J.P. Staerk J. Delhommeau F. Lacout C. Garcon L. Raslova H. Berger R. Bennaceur-Griscelli A. Villeval J.L. Constantinescu S.N. Casadevall N. Vainchenker 2005; PubMed Scopus Google Scholar). In the for cell line the of the Jak2V617F mutation in the erythroid leukemia cell line but in the erythroid cell line and Ref. R.L. Wadleigh M. Cools J. Ebert B.L. Wernig G. Huntly B.J. Boggon T.J. Wlodarska I. Clark J.J. Moore S. Adelsperger J. Koo S. Lee J.C. Gabriel S. Mercher T. D'Andrea A. Frohling S. Dohner K. Marynen P. Vandenberghe P. Mesa R.A. Tefferi A. Griffin J.D. Eck M.J. Sellers W.R. Meyerson M. Golub T.R. Lee S.J. Gilliland D.G. Cancer Cell. 2005; 7: 387-397Abstract Full Text Full Text PDF PubMed Scopus (2484) Google Scholar). a that has been to be a Jak kinase inhibitor R. N. J.A. PubMed Scopus Google was used in HEL Treatment of HEL cells with Jak inhibitor to a dose-dependent of cell growth in a with of a of there was inhibition of cell growth in HEL cells as with cells, which is consistent with recently (15Levine R.L. Wadleigh M. Cools J. Ebert B.L. Wernig G. Huntly B.J. Boggon T.J. Wlodarska I. Clark J.J. Moore S. Adelsperger J. Koo S. Lee J.C. Gabriel S. Mercher T. D'Andrea A. Frohling S. Dohner K. Marynen P. Vandenberghe P. Mesa R.A. Tefferi A. Griffin J.D. Eck M.J. Sellers W.R. Meyerson M. Golub T.R. Lee S.J. Gilliland D.G. Cancer Cell. 2005; 7: 387-397Abstract Full Text Full Text PDF PubMed Scopus (2484) Google Scholar). was inhibition of cell growth in the cells at Jak inhibitor and the was these that Jak inhibitor growth of HEL cells, it have tyrosine the of reduced cell growth induced by the Jak kinase at targets to be in cell growth. In the Jak inhibitor was to tyrosine of the Jak2 STAT5 activation at and tyrosine of Jak2 was reduced at that Jak kinase inhibitor also reduced cyclin D2 expression and increased p27Kip expression a for Jak2 in G1 phase to phase transition. cell cycle in to the inhibitor by was were or with Jak inhibitor and the different of cell cycle were The of cells in G1 phase increased to in cells that were for with Jak inhibitor to a dose-dependent the of cells in phase decreased to and in phase decreased to a in G1 a in and a in phase Jak inhibitor This suggests that Jak inhibitor to a significant G1 cell cycle in the cells, which is consistent with of cyclin D2 and p27Kip regulation by there was significant of cells in also at the in of cells, for increased of to the cell Using HEL cells, that treatment with Jak inhibitor to a in cells with cells of HEL cells to the drug to a small of in In the cells of the of These that Jak inhibitor G1 cell cycle primarily contributes to the reduced cell growth of HEL cells, in combination with a kinase inhibitor G1 cell cycle and in HEL HEL cells were or for with the of Jak inhibitor I. The in STAT5 as well as expression of STAT5, cyclin or p27Kip in cell were as cell cycle was in HEL cells for with the of Jak inhibitor HEL cells were with Jak inhibitor or as and cell in a of Jak2V617F for of HEL tyrosine kinase as that with the of the The that Jak inhibitor cell growth of HEL cells at cell growth is The of the Jak inhibitor also with a in tyrosine of the Jak2 it is that small molecule drug also other kinases at these used a Jak2-targeted HEL cells were transfected with four different regions in Jak2 or with as and were to Jak2 as reduced Jak2 with transfected cells in Jak2 expression also of with the and to a reduced STAT5 STAT5 with transfected These suggest that Jak2V617F expression is required for optimal of STAT5 at activation The inhibitor suggested that Jak activation regulates cell cycle and that inhibition of Jak2 G1 cell cycle arrest. with reduced cyclin D2 and increased p27Kip expression was to with reduced Jak2 expression and thus reduced of STAT5 the of Jak2 RNA cell growth of HEL cells was The of and to a in cell growth with transfected cells An of that there were between the Using for these in the that and are different the at the to the at of for including a a small in of of the with transfected cells This suggests that was the for reduced cell growth by Jak2 In contrast, there was in G1 cell cycle of between and within with and Similar to the cell cycle with transfected results that Jak2V617F is required for cell growth of HEL cells and Jak2 as a of cell cycle of p27Kip through the have been suggested by and E. J. Biol. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar, M. K. T. Science. 1995; PubMed Scopus Google Scholar, M. T. S. G. R. Griffin J.D. Blood. 1999; 93: PubMed Google Scholar, M. S. G. T. R. Griffin J.D. J. Biol. Full Text Full Text PDF PubMed Scopus Google to contribute to normal signaling as well as to by the oncogenic tyrosine have that the tyrosine kinase inhibitor to inhibition of in hematopoietic cells M. S. G. T. R. Griffin J.D. J. Biol. Full Text Full Text PDF PubMed Scopus Google Scholar). therefore also to Jak inhibitor in the HEL Jak inhibitor treatment was to have a small levels a treatment but reduced by a treatment with cells at the of the antioxidant N-acetylcysteine the expression of p27Kip and cyclin D2 in HEL and Jak inhibitor were to p27Kip expression as well as cyclin D2 levels consistent with for in the regulation of G1 phase to phase transition. was also to activation of STAT5 a activation These results that activation of the Jak2 pathway is required for optimal of in HEL cells and regulation of p27Kip activation of the Jak2 STAT5 is sufficient to levels of ROS, used a BaF3 cell line with constitutively active STAT5 F. Griffin J.D. Blood. PubMed Google Scholar). in the of growth were with cells or cells with as a for increased M. T. S. G. R. Griffin J.D. Blood. 1999; 93: PubMed Google Scholar). treatment by levels of active STAT5 expression to a significant in ROS, which was to the treatment In the of STAT5 in these cell was by active STAT5 also to a significant in p27Kip levels with growth cells in the of also in cyclin D2 levels in the of STAT5 through these results that activation of the pathway is sufficient for the of elevated levels of and cyclin D2 and the of the cell cycle inhibitor p27Kip. also at the of the NAC, and cell growth in HEL cells HEL cells were with NAC, or PDTC, and cell growth was in a to a dose-dependent in cell growth and reduced the cell by at of NAC, or these results suggest that a high is to cell growth in HEL the pathway is likely to contribute to elevated levels and the in p27Kip Jak2V617F and in BaF3 to the HEL cells, or BaF3 BaF3 cells are and be to growth by a variety of tyrosine kinases, as M. R. K. N. E. G. J.L. Griffin J.D. 1996; Google M. P. J.L. S. C. K. R. Cancer Res. 2003; Google or Jak2V617F in BaF3 cells or growth BaF3 cells to hyper-responsiveness as well as to partial factor-independent growth (15Levine R.L. Wadleigh M. Cools J. Ebert B.L. Wernig G. Huntly B.J. Boggon T.J. Wlodarska I. Clark J.J. Moore S. Adelsperger J. Koo S. Lee J.C. Gabriel S. Mercher T. D'Andrea A. Frohling S. Dohner K. Marynen P. Vandenberghe P. Mesa R.A. Tefferi A. Griffin J.D. Eck M.J. Sellers W.R. Meyerson M. Golub T.R. Lee S.J. Gilliland D.G. Cancer Cell. 2005; 7: 387-397Abstract Full Text Full Text PDF PubMed Scopus (2484) Google Scholar, 16James C. Ugo V. Le Couedic J.P. Staerk J. Delhommeau F. Lacout C. Garcon L. Raslova H. Berger R. Bennaceur-Griscelli A. Villeval J.L. Constantinescu S.N. Casadevall N. Vainchenker 2005; PubMed Scopus Google Scholar, J. A. Vainchenker Constantinescu S.N. J. Biol. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar). cells were for cells and for elevated and Jak2 expression levels that Jak2V617F induced partial growth in BaF3 cells in the of the or the Jak2 by cell growth in cell line Using the BaF3 and cells or cells with to Jak2V617F, cell cycle was in cells for of The of BaF3 cells small in cell cycle with cells a of cells in G1 phase and a in as well as a in phase In contrast, of the reduced the of cells in G1 phase and increased the of cells in phase a in G1 as well as a in phase and a in phase Jak2 have cell cycle This suggests that Jak2V617F promotes G1/S phase cell cycle transition in BaF3 The of to the of cells with BaF3 It be in the to the between these cells are because of or in the of at the of Jak2 the cells and cells to Jak2 or Jak2V617F were in for and the tyrosine of the was by The was to be tyrosine in cells but in cells or cells of Jak2 and proteins was in cell This suggests that Jak2V617F through the EpoR, and with other may be in part to activation of signaling mechanisms downstream of the In it be that C. Ugo V. Le Couedic J.P. Staerk J. Delhommeau F. Lacout C. Garcon L. Raslova H. Berger R. Bennaceur-Griscelli A. Villeval J.L. Constantinescu S.N. Casadevall N. Vainchenker 2005; PubMed Scopus Google have that BaF3 cells be by Jak2V617F, and it is that to phenotype. suggest that of the Jak2V617F signaling in BaF3 these used the cell line to the of Jak2 in the regulation of cyclin D2 and p27Kip. with the signaling mechanisms by Jak2V617F in HEL cells, expression of was sufficient to to expression of p27Kip and high expression levels of cyclin D2 with cells that were used as a The of p27Kip or the of cyclin D2 was growth in the cells line or in cells The regulation of p27Kip and cyclin D2 expression correlated with of STAT5 activation These cell but cells, G1 cell cycle within similar to HEL cells, expression of Jak2V617F was required for elevated levels of in cells The in by Jak2V617F was to the in to in cells and the in contrast, but the the of cyclin D2 by Jak2V617F growth was to the phenotype in the cells These in cells by Jak2V617F are consistent with the results obtained the cell line Jak2V617F in the regulation of cell cycle proteins and was to the mechanisms in by Jak2V617F and targets that aid in the development and of targeted for the treatment of myeloproliferative disorders. A Jak kinase inhibitor R. N. J.A. PubMed Scopus Google reduced cell growth of HEL cells with of The in cell growth correlated with reduced tyrosine of STAT5 activation STAT5 is a of Jak2 F. H. M. B. J. PubMed Scopus Google and and have implicated activation of STAT5 in by the C. F. M. Griffin J.D. Blood. PubMed Google Scholar). This is also of because activation of STAT5 by is sufficient to hematopoietic cells M. T. K. D. M. A. T. Mol. Cell. Biol. 1998; PubMed Scopus Google Scholar). It is that activation of transcription is a in myeloproliferative disorders. targets of STAT5 therefore additional cell growth may be a of reduced STAT5 or may involve other Jak2 as H. H. T. F. J. Biol. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar). The in growth inhibition by Jak inhibitor was to be G1 cell cycle with decreased cyclin D2 expression and increased p27Kip expression. proteins and p27Kip are critical cell cycle for phase H. R.A. Cell. 65: Full Text PDF PubMed Scopus Google Scholar, A. B. Proc. Natl. Acad. Sci. U. S. A. PubMed Scopus Google Scholar, K. M.J. J. Roberts J.M. A. Genes Dev. PubMed Scopus Google Scholar, H. T. Cell. Full Text PDF PubMed Scopus Google Scholar). also a small and consistent in that for the growth inhibition by Jak inhibitor I. In (15Levine R.L. Wadleigh M. Cools J. Ebert B.L. Wernig G. Huntly B.J. Boggon T.J. Wlodarska I. Clark J.J. Moore S. Adelsperger J. Koo S. Lee J.C. Gabriel S. Mercher T. D'Andrea A. Frohling S. Dohner K. Marynen P. Vandenberghe P. Mesa R.A. Tefferi A. Griffin J.D. Eck M.J. Sellers W.R. Meyerson M. Golub T.R. Lee S.J. Gilliland D.G. Cancer Cell. 2005; 7: 387-397Abstract Full Text Full Text PDF PubMed Scopus (2484) Google reported a similar small in HEL cells by inhibitor at a but in cell cycle were the of Jak2V617F in cell also used a Jak2-targeted with the inhibitor of the four Jak2 reduced Jak2 expression and to a in STAT5 tyrosine These the between the expression of Jak2 and STAT5 by activation and the of the Jak kinase inhibitor I. Jak2 also reduced cell growth in HEL cells with transfected Similar to the inhibitor the Jak2 induced G1 cell cycle with a decreased expression of cyclin reduced Jak2 expression induced Using a similar C.S. Lim S.K. D'Agati V. Costantini F. Genes Dev. 1996; 10: 154-164Crossref PubMed Scopus (353) Google that Jak2 reduced erythroid in cells which be by erythropoietin the Jak2 cell growth cells were with normal cells C. Ugo V. Le Couedic J.P. Staerk J. Delhommeau F. Lacout C. Garcon L. Raslova H. Berger R. Bennaceur-Griscelli A. Villeval J.L. Constantinescu S.N. Casadevall N. Vainchenker 2005; PubMed Scopus Google Scholar). the expression levels of Jak2 in these cells in to Jak2 or were the for active Jak2 expression in HEL cells the V617F It be to the combination of Jak2 and Jak inhibitor the of approach for the inhibitor and M.W. B.J. Blood. 2005; PubMed Scopus Google Scholar). of signaling by Jak2V617F is the for expression of Jak2V617F BaF3 cells C. Ugo V. Le Couedic J.P. Staerk J. Delhommeau F. Lacout C. Garcon L. Raslova H. Berger R. Bennaceur-Griscelli A. Villeval J.L. Constantinescu S.N. Casadevall N. Vainchenker 2005; PubMed Scopus Google that of cell cycle erythropoietin receptor An be that different in associated with Jak2V617F are to genes as growth The of of these in a phenotype additional is the of in signaling through the inhibition of Jak2 activity in HEL cells and the active STAT5 in BaF3 cells were to ROS, likely in part through the This is also by that cells have elevated levels of with the cell were and to cell growth in a dose-dependent consistent with of a high for cell growth in these that treatment of a growth hematopoietic cell line with the is sufficient to promote G1 to phase cell cycle transition M. T. S. G. R. Griffin J.D. Blood. 1999; 93: PubMed Google and are to G1 cell cycle in a variety of cell R. M. H. P.C. Cancer Res. 2003; Google Scholar, T. I. J. Biol. Full Text Full Text PDF PubMed Scopus Google Scholar, M. A. J.M. Wu J. 1998; PubMed Scopus Google Scholar). It is that regulation of the cell cycle inhibitor p27Kip downstream of STAT5 in combination with redox-dependent processes may contribute to the regulation of G1/S phase transition. The mechanisms in the of p27Kip by constitutively active STAT5 are of and In of the of in Jak2 is of clear and potential in patients with myeloproliferative disorders. Using a Jak kinase have characterized the G1/S phase transition and a major of Jak2V617F is G1 cell cycle it is likely that the of pathway be increased in by combination with antioxidant or that the expression of cyclin D2 or p27Kip.
41
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
Chloé James, Valérie Ugo, Jean‐Pierre Le Couedic et al. · Nature · 2005 · 3.5K citations
A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders
Róbert Královics, Francesco Passamonti, Andreas Buser et al. · New England Journal of Medicine · 2005 · 3.5K citations · Full text
Life Sciences, Genetics, Hematology +15
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
E. Joanna Baxter, Linda M. Scott, Peter J. Campbell et al. · The Lancet · 2005 · 3.4K citations
Life Sciences, Genetics, Hematology +14